Parramatta. Schott on short list

Kerry Schott, MD of Sydney Water, based in Parramatta, a former infrastructure investment banker and deputy secretary of the NSW Treasury, is a likely candidate for the short list for the position of NSW Treasury secretary. Her five-year contract expires in August. Her infrastructure credentials could also put her in the running for the position of chief executive of the government’s new advisory body, Infrastructure NSW, according to The Australian Financial Review.

North Ryde. Newly created position at uni

David Wright has been appointed to a newly created position in Macquarie University's executive team, that of executive director - strategy development and implementation. Mr Wright served previously as managing director of the university's commercial arm, Access Macquarie Limited.

Sydney Olympic Park. Launch of strategy

The official launch of TAFE NSW’s latest Manufacturing and Engineering Strategy will take place, on May 2, during NSW Manufacturing Week 2011, at the Novotel Hotel, in Sydney Olympic Park.

Region. EOI in CarLovers Group

Ken Whittingham and Atle Crowe-Maxwell as receivers and managers of the CarLovers Group are seeking expressions of interest for the sale of the business and assets, which include 22 car was sites, some in Western Sydney.

Newington. Poker machine sales up

After poker machine company, at Newington, Ainsworth Game Technology’s profits were held back in recent years by high research and development costs, the expense of entering new markets overseas and a coinciding lack of scale at home, its growing sales are finally flowing through to the bottom line, according to CEO, Danny Gladstone. The company controls a little more than 8 per cent of the Australian market in terms of installed machines, but its share of shipments has been tracking well above that level for more than a year.

Camellia. API's fortunes could be turning

The fortunes of Australia Pharmaceutical Industries (API), at Camellia, could be turning, compared with its competitor, Sigma Pharmaceutical, after API’s first-half result convinced several brokers the worst may be over for the drug distributor, according to The Australian Financial Review. APO posted flat revenue and underlying net profit that excludes one-off costs of $1.85 billion and $11.2 million respectively.